Natriuretic peptide [NP; B‐type NP (BNP), N‐terminal proBNP (NT‐proBNP), and
midregional proANP (MR‐proANP)] concentrations are quantitative plasma biomarkers for …

For patients presenting with acute dyspnea, an incorrect diagnosis could increase the
mortality risk. When used in the evaluation of patients with acute symptoms, brain natriuretic …

Natriuretic peptide (NP) levels (B‐type natriuretic peptide (BNP) and N‐terminal proBNP)
are now widely used in clinical practice and cardiovascular research throughout the world …

The long-predicted endocrine function of the heart has been proven by the discovery of atrial
natriuretic peptide (atrial natriuretic factor, A-type natriuretic peptide; ANP) 20 years ago …

Objectives To determine and compare the diagnostic accuracy of serum natriuretic peptide
levels (B type natriuretic peptide, N terminal probrain natriuretic peptide (NTproBNP), and …

Diagnosing heart failure is often difficult due to the non‐specific nature of symptoms, which
can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been …

Cardiac biomarkers play an important role in heart failure. The family of natriuretic peptides,
especially B-type natriuretic peptide, was identified as a valued diagnostic and prognostic …

B-type natriuretic peptide (BNP) and NT-proBNP have been shown to be extremely helpful
in the diagnosis and management of patients with heart failure (HF). These neurohormones …

B-Type natriuretic peptide was discovered in 1988. 1 Proof of the existence of amino-
terminal pro–B-type natriuretic peptide (NT-proBNP) in the human circulation and its …

Background: Concomitant occurrence of kidney disease (KD) and heart failure (HF) is
common and associated with poor outcomes. Natriuretic peptide studies have typically …